Nutropin Depot is a drug owned by Genentech Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 05, 2014. Details of Nutropin Depot's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5654010 | Composition for sustained release of human growth hormone |
Aug, 2014
(10 years ago) |
Expired
|
| US5656297 | Modulated release from biocompatible polymers |
Jul, 2014
(10 years ago) |
Expired
|
| US6051259 | Composition for sustained release of human growth hormone |
Dec, 2012
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Nutropin Depot is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nutropin Depot's family patents as well as insights into ongoing legal events on those patents.
Nutropin Depot's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nutropin Depot's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 05, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nutropin Depot Generics:
There are no approved generic versions for Nutropin Depot as of now.
Alternative Brands for Nutropin Depot
Nutropin Depot which is used for treating growth failure in children with inadequate growth hormone secretion., has several other brand drugs in the same treatment category and using the same active ingredient (Somatropin Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Novo Nordisk Inc |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Somatropin Recombinant. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Emd Serono |
| |||
| Genentech |
| |||
| Novo Nordisk Inc |
| |||
| Pharmacia And Upjohn |
|
About Nutropin Depot
Nutropin Depot is a drug owned by Genentech Inc. It is used for treating growth failure in children with inadequate growth hormone secretion. Nutropin Depot uses Somatropin Recombinant as an active ingredient. Nutropin Depot was launched by Genentech in 1999.
Approval Date:
Nutropin Depot was approved by FDA for market use on 22 December, 1999.
Active Ingredient:
Nutropin Depot uses Somatropin Recombinant as the active ingredient. Check out other Drugs and Companies using Somatropin Recombinant ingredient
Treatment:
Nutropin Depot is used for treating growth failure in children with inadequate growth hormone secretion.
Dosage:
Nutropin Depot is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 13.5MG/VIAL | INJECTABLE | Discontinued | INJECTION |
| 22.5MG/VIAL | INJECTABLE | Discontinued | INJECTION |
| 18MG/VIAL | INJECTABLE | Discontinued | INJECTION |